This is the authors' abstract. We don't add key points for this paper.
Patient outcomes may differ from randomized trial averages. We aimed to predict benefit from FOLFOXIRI versus infusional fluorouracil, leucovorin, and oxaliplatin/fluorouracil, leucovorin, and irinotecan (FOLFOX/FOLFIRI), both plus bevacizumab, in patients with metastatic colorectal cancer (mCRC).
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Bond et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: